Chalk up another exciting development for the stem cell and regenerative medicine field in 2014 related to diabetes. It’s been a huge year. (Update: read my Fall 2019 interview with ViaCyte here.) For the first time ever, an ES cell-based device has been transplanted into a diabetic patient. ViaCyte working together with Dr. Robert Henry […]
Diabetes Stem Cell Milestone: ViaCyte Transplants 1st Patient Read More »
A new patent dispute has exploded in the stem cell field related to induced pluripotent stem (iPS) cells. What’s going on? In 2006, Shinya Yamanaka reported cellular reprogramming to create mouse induced pluripotent stem (iPS) cells in Cell and the next year multiple groups along with Yamanaka’s reported creating human iPS cells. It’s no exaggeration
Challenge tries to cancel Yamanaka iPS cell patent Read More »
The Knoepfler Lab conducts stem and cancer cell as well as chromatin/epigenetics research at the UC Davis School of Medicine. Our team has two big picture goals: (1) catalyzing the development of more effective treatments for cancers based on targeting stem cell-related machinery in tumorigenesis and (2) producing safer stem cell-based regenerative medicine therapies. We are particularly
A relatively newly recognized, important player in the stem cell field is a molecule called histone H3.3. Histones are key components of chromatin with integral roles in regulating almost all aspects of cell behavior through orchestrating functions such as transcription and chromosome segregation. Histone H3.3 knockout My lab has just (April 9) published new studies
Histone H3.3: giving cells epigenetic flexibility Read More »
I have a poll running regarding who would have been the best choice to share the Nobel Prize with Shinya Yamanaka and John Gurdon, and so far the winner is Ian Wilmut, who cloned the first mammal, Dolly the sheep. I should have included another option to indicate the possible preference that NO ONE should
Wilmut voted most-deserving of 3rd Nobel slot with Yamanka & Gurdon in poll Read More »
Yamanaka may have found a way to give exogenous Myc the boot from the iPS cell universe. It has always been a frustration in the iPS cell field that Myc, a proto-oncogene, is so important for reprogramming. Yes, you can make iPS cells (especially mouse) without Myc, but it can be orders of magnitude harder,
New iPS cell method: drop Myc or not yet? Read More »